Moringa Oleifera is a medicinal plant that is used in the production of cytotoxic agents, which are used in cancer treatment to prevent the division and spread of cancer cells. The present study investigates the cytotoxic activity of NiO nanoparticles (NiONPs) produced by means of green synthesis using Moringa Oleifera on human cancer cell lines (HEP-G2). The antibacterial activity of these nanoparticles was also evaluated in relation to the carbapenem (CRO), chloramphenicol (C), ampicillin (AM), cephalothin (KF) and meropenem (MEM) antibiotics, as well as Gram-positive Streptococcus mutans (S. mutans) (+) and Gram-negative Escherichia coli (E. coli) (-) bacteria. NiONPs demonstrated a high cytotoxic value of 91.05% against HEP-G2 cancer cells. The study established that 1 µg/ml resulted in 85.2% of HEP-G2 cancer cell death. The study demonstrated high levels of antibacterial resistance at low concentrations (0.0315 µg/mol). The high sensitivity of the bacteria was determined for Chloramphenicol (C) and Meropenem (MEM) for S. mutans and for all antibiotics for E. coli bacteria. It was demonstrated that S. mutans and E. coli bacteria exhibited high susceptibility to only chloramphenicol (C) and meropenem (MEM) antibiotics. The NiONPs demonstrated a spherical morphology, with grain sizes ranging from 24 to 40 nm, and a surface plasma resonance (SPR) peak at 356 nm. NiONPs prepared with Moringa oleifera plant are suitable for biomedical applications due to their very high level of toxicity against HEP-G2, strong antibiotic sensitivity and antimicrobial activity against S. mutans and E. coli.
SeNPs were synthesized via chemical reduction and physical pulsed laser ablation techniques. Stable, spherical nanoparticles with TEM diameters ranging from 20 to 150 nm (mean ± SD: 28.5 ± 7.2 nm and 33.8 ± 6.4 nm for the chemical and physical methods, respectively) were obtained. The characteristic absorption peaks at 310 nm and 371 nm were detected for SeNPs produced by chemical reduction and physical pulsed laser ablation, respectively. The band gap values were found to be 1.74 eV and 1.92 eV, respectively. Zeta potential analysis confirmed moderate colloidal stability (23.67 mV and 25.17 mV for chemical and physical reduction, respectively). The antibacterial activities of the SeNPs against E. coli , Klebsiella spp. , Pseudomonas spp. and Staphylococcus spp. were evaluated using the agar well diffusion method. SeNPs synthesized by the chemical reduction method formed inhibition zones of 10, 14, 18, 20 and 27 mm ( E. coli ); 9–18 mm ( Staphylococcus spp. ); 10–17 mm ( Klebsiella spp. ); and 8–16 mm (Pseudomonas spp.). Particles synthesized by physical pulsed laser ablation formed equivalent zones of 9–24 mm, 8–16 mm, 9–17 mm, and 7–15 mm. A particularly notable result was the strain- and dose-dependent difference identified by one-way ANOVA (F = 3304.3, p < 1 × 10⁻ 12 ) at 1000 μg/mL for chemical SeNPs. Anticancer activity was evaluated against CaCo-2 colon adenocarcinoma cells using the MTT assay. Chemically synthesized SeNPs were found to reduce viability from 90 ± 4.5% (6.25 μg/mL) to 18 ± 1.1% (200 μg/mL) with an IC₅₀ of approximately 57 μg/mL (R 2 = 0.996). Physically prepared SeNPs were found to have viability ranging from 91.8% to 33.3%, with an IC₅₀ value of approximately 36 μg/mL. The Pearson correlation between log [dose] and viability was found to be highly negative (r = − 0.979 to − 0.992, p < 0.001). Overall, SeNPs exhibited dose-dependent antibacterial activity (> 27 mm inhibition) and anticancer activity (IC₅₀ ≤ 57 μg/mL), with the synthesis route affecting efficacy. These quantitative observations confirm the SeNPs’ potential as multifunctional nanotherapeutics, necessitating in vivo studies to definitively determine pharmacokinetics (PK), safety, and mechanistic pathways.
Melanoma is among the most aggressive forms of skin cancer, characterized by high metastatic potential and limited responsiveness to conventional chemotherapy. Paclitaxel (PTX) is an efficacious anticancer agent; however, its clinical utility in melanoma is restricted by poor aqueous solubility, non-specific biodistribution, and dose-limiting systemic toxicity. To overcome these limitations, this study aimed to develop and evaluate folate-targeted poly(lactic-co-glycolic acid) nanoparticles (FA-PTX-PLGA-NPs) as a targeted nanotherapeutic approach for melanoma treatment. Paclitaxel-loaded PLGA nanoparticles were synthesized through an emulsion–solvent evaporation process, followed by surface functionalization with folic acid to promote targeting by folate receptor. Nanosized particle formation with acceptable stability and drug encapsulation was confirmed by physicochemical characterization. The anticancer efficacy of FA-PTX-PLGA-NPs in B16 melanoma cells was assessed using cell viability and apoptosis assays compared with free paclitaxel and non-targeted PTX-PLGA nanoparticles. The findings indicated a distinct formulation-dependent therapeutic response. The most pronounced reduction in cell viability (25.94 ± 5.18%) was observed with FA-PTX-PLGA-NPs compared to free PTX (59.07 ± 5.98%) and PTX-PLGA nanoparticles (42.90 ± 4.10%). Consistently, apoptosis analysis revealed a significant increase in apoptotic cell populations following treatment with FA-PTX-PLGA-NPs (68.47 ± 6.53%) compared to free PTX and non-targeted nanoparticles ( p < 0.001). These observations suggest that the increased anticancer potency is primarily mediated through apoptosis, with a strong association to folate receptor–mediated cellular uptake. Finally, folate-targeted PLGA nanoparticles could markedly enhance the therapeutic properties of paclitaxel against melanoma by improving intracellular drug delivery and promoting apoptotic cell death. It is worth noting that such a targeted nanocarrier platform may present a promising platform for melanoma chemotherapy and needs to be further evaluated in vivo to show its translational potential. This study presents a novel folate-targeted PLGA nanoparticle system for enhanced delivery of paclitaxel in melanoma cells, demonstrating improved cytotoxic and apoptotic effects compared to non-targeted nanoparticles.